Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12292042 | 1.00 | CCR2 (0.92) | CCR2ALDH1A1POLBRAB9AKDM4E | |
| SCHEMBL195373 | 0.96 | CCR2 (1.00) | CCR2ALDH1A1RAB9AKDM4E | |
| SCHEMBL13006178 | 0.96 | CCR2 (1.00) | CCR2ALDH1A1RAB9AKDM4E | |
| SCHEMBL12292044 | 0.94 | CCR2 (0.97) | CCR2ALDH1A1RAB9AKDM4E | |
| SCHEMBL12292046 | 0.91 | CCR2 (0.81) | CCR2ALDH1A1POLBEPHX1 | |
| SCHEMBL3259739 | 0.86 | CCR2 (0.69) | CCR2KDM4E | |
| SCHEMBL2971927 | 0.86 | CCR2 (0.69) | CCR2ALDH1A1RAB9AKDM4E | |
| SCHEMBL12799207 | 0.83 | CCR2 (0.77) | CCR2ALDH1A1RAB9AKDM4E | |
| SCHEMBL13483782 | 0.83 | CCR2 (0.77) | CCR2ALDH1A1RAB9AKDM4E | |
| SCHEMBL13013126 | 0.82 | CCR2 (0.75) | CCR2RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141460-A1 | Anti-inflammatory Compositions | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-8853200-B2 | Treatment of rheumatoid arthritis with 3-amino lactam compounds | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| EP-2572716-A1 | Anti-inflammatory Composition | Cambridge Enterprise Limited (GB) | 2013-03-27 | — | — | EP | disclosed |
| US-20100324089-A1 | Anti-inflammatory composition | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| EP-2185151-A1 | ANTI-INFLAMMATORY COMPOSITION | Cambridge Enterprise Ltd. (GB) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016390-A1 | ANTI-INFLAMMATORY COMPOSITION | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141460-A1 | Anti-inflammatory Compositions | TNF, PTGES2, IL1B | CCR2 94/4885ALDH1A1 668/4885POLB 3842/4885 |
| US-20100324089-A1 | Anti-inflammatory composition | TNF, IL1B, IL1A | CCR2 85/4885ALDH1A1 938/4885POLB 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.